journal
https://read.qxmd.com/read/37731148/t-large-granular-lymphocyte-frequencies-and-correlates-in-disease-states-detected-by-multiparameter-flow-cytometry-in-pediatric-and-young-adult-population
#1
JOURNAL ARTICLE
Manisha Gadgeel, Ishaq Al Kooheji, Batool Al-Qanber, Steven Buck, Süreyya Savaşan
T-large granular lymphocytes (T-LGL) characterized by dim CD5 staining, although not completely understood, have unique roles in the immune system. Expansion of peripheral blood (PB) clonal T-LGL populations is associated with various entities in adults. We have previously demonstrated clonal T-LGL proliferations in pediatric immune dysregulation/inflammatory/proliferative conditions. However, T-LGL populations have not been studied in broader spectrum pathologies. In this study we evaluated sizes and correlates of T-LGL populations in the pediatric and young adult populations with various disease states...
September 21, 2023: Annals of Hematology
https://read.qxmd.com/read/37731147/a-real-life-study-of-daratumumab-bortezomib-dexamethasone-d-vd-in-lenalidomide-exposed-refractory-multiple-myeloma-patients-a-report-from-the-triveneto-myeloma-working-group
#2
JOURNAL ARTICLE
Gregorio Barilà, Francesca Maria Quaglia, Anna Furlan, Norbert Pescosta, Angela Bonalumi, Chiara Marcon, Anna Pascarella, Martina Tinelli, Elena De March, Albana Lico, Roberto Sartori, Cristina Clissa, Giovanni De Sabbata, Davide Nappi, Marika Porrazzo, Roberta De Marchi, Laura Pavan, Alberto Tosetto, Filippo Gherlinzoni, Mauro Krampera, Renato Bassan, Francesca Patriarca, Gianpietro Semenzato, Renato Zambello
Treatment of lenalidomide refractory (Len-R) multiple myeloma (MM) patients still represents an unmet clinical need. In the last years, daratumumab-bortezomib-dexamethasone (D-VD) combination was extensively used in this setting, even though only a small fraction of Len-R patients was included in the pivotal trial. This real-life study aimed to evaluate the efficacy and safety of the D-VD regimen in a cohort that exclusively enrolled Len exposed or refractory MM patients. The study cohort included 57 patients affected by relapsed/refractory MM...
September 20, 2023: Annals of Hematology
https://read.qxmd.com/read/37731146/the-role-of-ruxolitinib-treatment-in-jak-mutated-ph-like-acute-lymphoblastic-leukemia
#3
LETTER
Ozlem Candan, Derya Demirtas, Ahmet Mert Yanik, Isik Atagunduz, Tayfur Toptas
No abstract text is available yet for this article.
September 20, 2023: Annals of Hematology
https://read.qxmd.com/read/37728735/successful-use-of-venetoclax-combined-with-azacitidine-in-isolated-extramedullary-relapse-of-acute-myeloid-leukemia-after-allogeneic-hematopoietic-stem-cell-transplantation-a-case-report
#4
LETTER
Qingqing Lin, Peipei Ye, Tiantian Wang, Ying Lu
No abstract text is available yet for this article.
September 20, 2023: Annals of Hematology
https://read.qxmd.com/read/37726493/excellent-outcome-of-stem-cell-transplantation-for-sickle-cell-disease
#5
JOURNAL ARTICLE
Tanja Vallée, Irene Schmid, Lisa Gloning, Martina Bacova, Jutta Ahrens, Tobias Feuchtinger, Christoph Klein, Vincent D Gaertner, Michael H Albert
Many sickle cell disease (SCD) patients lack matched family donors (MFD) or matched unrelated donors (MUD), implying haploidentical donors (MMFD) as a logical donor choice. We used a reduced toxicity protocol for all donor types. We included 31 patients (2-22 years) with MFD (n = 15), MMFD (10), or MUD (6) HSCT and conditioning with alemtuzumab/ATG, thiotepa, fludarabine and treosulfan, and post-transplant cyclophosphamide for MMFD. After the initial six patients, treosulfan was replaced by targeted busulfan (AUC 65-75 ng*h/ml)...
September 19, 2023: Annals of Hematology
https://read.qxmd.com/read/37726492/mir-603-promotes-cell-proliferation-and-differentiation-by-targeting-trkb-in-acute-promyelocytic-leukemia
#6
JOURNAL ARTICLE
Huibo Li, Jinxiao Hou, Yueyue Fu, Yanqiu Zhao, Jie Liu, Dan Guo, Ruiqi Lei, Yiting Wu, Linqing Tang, Shengjin Fan
Arsenic trioxide (ATO) treatment effectively prolongs the overall survival of patients with acute promyelocytic leukemia (APL). Mutations in the oncogene PML::RARA were found in patients with ATO-resistant and relapsed APL. However, some relapsed patients do not have such mutations. Here, we performed microarray analysis of samples from newly diagnosed and relapsed APL, and found different microRNA (miRNA) expression patterns between these two groups. Among the differentially expressed miRNAs, miR-603 was expressed at the lowest level in relapsed patients...
September 19, 2023: Annals of Hematology
https://read.qxmd.com/read/37723307/hypomethylating-agents-plus-modified-priming-regimens-compared-with-venetoclax-based-regimens-based-on-molecular-characteristics-for-newly-diagnosed-patients-with-acute-myeloid-leukemia-a-multi-center-cohort-study
#7
JOURNAL ARTICLE
Guangyang Weng, Jingya Huang, Xin He, Tingting Xue, Linlin Yang, Yu Zhang, Guopan Yu, Zhiqiang Sun, Dongjun Lin, Lan Deng, Xinquan Liang, Jie Xiao, Hongyu Zhang, Ziwen Guo, Hua Jin, Qifa Liu, Xin Du
Venetoclax (VEN)-based regimens are the standard of care for elderly or unfit patients with newly diagnosed (ND) acute myeloid leukemia (AML). Some single-arm studies have implied that hypomethylating agents (HMAs) plus priming regimens may potentially provide an alternative therapeutic approach, owing to encouraging efficacy seen. However, no comparative data exists yet regarding these two treatment approaches. In this retrospective multi-center cohort study, we enrolled 294 ND AML patients, allocating 167 to the HMA + priming group and 127 to the VEN-based group...
September 18, 2023: Annals of Hematology
https://read.qxmd.com/read/37718327/endothelial-activation-and-stress-index-as-a-prognostic-factor-of-diffuse-large-b-cell-lymphoma-the-report-from-the-nationwide-multi-center-thai-lymphoma-study-group
#8
JOURNAL ARTICLE
Ronakrit Thanhakun, Kitsada Wudhikarn, Udomsak Bunworasate, Thanawat Rattanathammethee, Lalita Norasetthada, Piyapong Kanya, Juthatip Chaloemwong, Somchai Wongkhantee, Pisa Phiphitaporn, Kanchana Chansung, Dusit Jit-Ueakul, Chonlada Laoruangroj, Kannadit Prayongratana, Peerapon Wong, Jakrawadee Julamanee, Arnuparp Lekhakula, Suporn Chuncharunee, Pimjai Niparuck, Nonglak Kanitsap, Nisa Makruasi, Tawatchai Suwanban, Pannee Praditsuktavorn, Archrob Khuhapinant, Tanin Intragumtornchai
Several prognostic models have been introduced to predict outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Endothelial activation and stress index (EASIX) is a surrogate of endothelial dysfunction which has been shown to predict outcomes of patients with various hematologic malignancies. However, the prognostic implication of EASIX for DLBCL is limited and warrants exploration. We conducted a retrospective study enrolling adult DLBCL patients including a discovery cohort from the single-centered university hospital database and a validation cohort from the independent nationwide multi-center registry...
September 18, 2023: Annals of Hematology
https://read.qxmd.com/read/37713125/the-experience-of-diagnosis-and-treatment-for-tafro-syndrome
#9
JOURNAL ARTICLE
Xiaolong Wu, Xudong Zhang, Siyu Qian, Cunzhen Shi, Xin Li, Xiaoyan Feng, Linan Zhu, Jingjing Ge, Zhaoming Li, Mingzhi Zhang
Early identification, diagnosis and treatment of TAFRO syndrome are very importants. We retrospectively analysed 6 patients with TAFRO syndrome. Their clinical manifestations, treatment methods, survival and other aspects were summarized. All patients were pathologically diagnosed with Castleman's disease, with fever, an inflammatory storm state and varying degrees of anasarca. All patients received steroid therapy; four of them also received chemotherapy, and 1 received rituximab. Of the 3 patients with severe disease, only 1 patient who received the recommended dose of glucocorticoids survived...
September 15, 2023: Annals of Hematology
https://read.qxmd.com/read/37713124/c-myc-inhibits-laptm5-expression-in-b-cell-lymphomas
#10
JOURNAL ARTICLE
Yanqing Zhang, Xin Zhang, Yi Zhang, Han Xu, Zichen Wei, Xin Wang, Yan Li, Junrong Guo, Fan Wu, Xiao Fang, Lei Pang, Bin Deng, Duonan Yu
Myc is a pivotal protooncogenic transcription factor that contributes to the development of almost all Burkitt's lymphomas and about one-third of diffuse large B-cell lymphomas. How B-cells sustain their uncontrolled proliferation due to high Myc is not yet well defined. Here, we found that Myc trans-represses the expression of murine LAPTM5, a gene coding a lysosome-associated protein, by binding to two E-boxes in the LAPTM5 promoter. While the product of intact mRNA (CDS+3'UTR) of LAPTM5 failed to suppress the growth of B-lymphomas, either the protein coded by coding sequence (CDS) itself or the non-coding 3'-untranslated region (3'UTR) mRNA was able to inhibit the growth of B-lymphomas...
September 15, 2023: Annals of Hematology
https://read.qxmd.com/read/37713123/a-case-of-sudden-hearing-loss-in-a-patient-with-chronic-myelomonocytic-leukemia
#11
JOURNAL ARTICLE
Rodrick Babakhanlou, Marc Ellie-Nader, Yesid Alvarado
Chronic myelomonocytic leukemia is a myeloid stem cell disease characterized by an abnormal production and accumulation of monocytic cells in association with other signs of myeloproliferation. Extramedullary manifestations of CMML are common and can affect the spleen, liver skin, and lymph nodes. However, otologic manifestations are extremely rare and could have occurred from either direct leukemic infiltration, hemorrhage of the cochlea, labyrinth, leukostasis, or infection. There is no standard treatment protocol for sensorineural hearing loss in CMML patients...
September 15, 2023: Annals of Hematology
https://read.qxmd.com/read/37710140/safe-and-successful-teclistamab-treatment-in-very-elderly-multiple-myeloma-mm-patients-a-case-report-and-experience-from-a-total-of-three-octogenarians
#12
LETTER
Martin Philipp Dieterle, Gila Mostufi-Zadeh-Haghighi, Jan Wilhelm Kus, Christopher Wippel, Zacharias Brugger, Cornelius Miething, Ralph Wäsch, Monika Engelhardt
No abstract text is available yet for this article.
September 15, 2023: Annals of Hematology
https://read.qxmd.com/read/37704875/bcma-targeting-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-and-or-refractory-multiple-myeloma
#13
REVIEW
Jiamin Fang, Fuling Zhou
Recently, many new therapies have improved the outcomes of patients with relapsed and/or refractory multiple myeloma (RRMM). Nevertheless, recurrence is still unavoidable, and better treatment choices for RRMM are urgently needed. The clinical success of Chimera antigen receptor (CAR) T cell therapy in many hematological diseases, including leukemia and lymphoma, has drawn considerable attention to RRMM. As CAR T cell therapy continues to mature and challenge traditional therapies, it is gradually changing the treatment paradigm for MM patients...
September 13, 2023: Annals of Hematology
https://read.qxmd.com/read/37704874/alternative-treatment-modality-for-severe-aplastic-anemia-in-a-resource-limited-setting-a-single-institution-prospective-cohort-study-from-upper-egypt
#14
JOURNAL ARTICLE
Mervat A M Youssef, Mohammed H Ghazaly, Mai A Abdelfattah
This study compared the efficacy and safety of CsA monotherapy with eltrombopag (E-PAG) + CsA combined treatment in children with severe aplastic anemia (SAA). The study including 30 children had SAA. Ten were a retrospective cohort treated with CsA monotherapy. The other 20 were prospective cohort received E-PAG + CsA. All patients were evaluated for partial (PR) and complete (CR) hematological response at 3, 6, and 12 months. overall response (OR), overall survival rates (OS), and treatment safety. OR for the E-PAG patients was 40% after 3 months of therapy...
September 13, 2023: Annals of Hematology
https://read.qxmd.com/read/37702823/clonal-hematopoiesis-with-tet2-mutations-spawning-synchronous-primary-central-nervous-system-lymphoma-and-myelodysplastic-syndrome
#15
LETTER
Hannes Treiber, Christina Ganster, Julie Schanz, Joji Shimono, Sabrina Zechel, Nilofar Pohanyar, Christian Riedel, Christine Stadelmann, Detlef Haase, Lorenz Trümper, Björn Chapuy, Gerald G Wulf
No abstract text is available yet for this article.
September 13, 2023: Annals of Hematology
https://read.qxmd.com/read/37702822/clinical-and-prognostic-role-of-sarcopenia-based-on-masticatory-muscle-index-on-mr-images-in-patients-with-extranodal-natural-killer-t-cell-lymphoma-nasal-type
#16
JOURNAL ARTICLE
Tianzi Xu, Yi Li, Yixin Liu, Biao Ning, Huijing Wu, Yongchang Wei
Sarcopenia is known to be associated with an increased risk of adverse outcomes in a variety of malignancies, but its impact in extranodal natural killer/T cell lymphoma, nasal type (ENKTL-NT) is unknown. The aim of this study was to explore the prognostic relevance of sarcopenia defined by MRI-based masticatory muscle index in ENKTL-NT patients. A total of 112 patients with newly diagnosed ENKTL-NT who underwent cranial magnetic resonance imaging (MRI) were enrolled. The masticatory skeletal muscle index (M-SMI) was measured based on T2-weighted MR images and sarcopenia was defined by M-SMI<5...
September 13, 2023: Annals of Hematology
https://read.qxmd.com/read/37702821/spliceosome-mutations-are-associated-with-clinical-response-in-a-phase-1b-2-study-of-the-plk1-inhibitor-onvansertib-in-combination-with-decitabine-in-relapsed-or-refractory-acute-myeloid-leukemia
#17
JOURNAL ARTICLE
Peter J P Croucher, Maya Ridinger, Pamela S Becker, Tara L Lin, Sandra L Silberman, Eunice S Wang, Amer M Zeidan
PLK1 is overexpressed in acute myeloid leukemia (AML). A phase 1b trial of the PLK1 inhibitor onvansertib (ONV) combined with decitabine (DAC) demonstrated initial safety and efficacy in patients with relapsed/refractory (R/R) AML. The current study aimed to identify molecular predictors of response to ONV + DAC in R/R AML patients. A total of 44 R/R AML patients were treated with ONV + DAC and considered evaluable for efficacy. Bone marrow (BM) samples were collected at baseline for genomic and transcriptomic analysis (n = 32)...
September 13, 2023: Annals of Hematology
https://read.qxmd.com/read/37700194/autologous-hematopoietic-stem-cell-transplantation-improves-survival-outcomes-in-peripheral-t-cell-lymphomas-a-multicenter-retrospective-real-world-study
#18
JOURNAL ARTICLE
Meng Wu, Fengrong Wang, Shihua Zhao, Yajun Li, Wenrong Huang, Bo Nie, Haisheng Liu, Xiaoqian Liu, Wei Li, Haifeng Yu, Kun Yi, Fei Dong, Yujun Dong, Chenglu Yuan, Xuehong Ran, Xiubin Xiao, Weiping Liu, Jun Zhu
The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute...
September 12, 2023: Annals of Hematology
https://read.qxmd.com/read/37695378/a-prospective-multicenter-observational-study-of-ixazomib-plus-lenalidomide-dexamethasone-in-patients-with-relapsed-refractory-multiple-myeloma-in-japan
#19
JOURNAL ARTICLE
Yuichi Horigome, Masaki Iino, Yoriko Harazaki, Takahiro Kobayashi, Hiroshi Handa, Yasushi Hiramatsu, Taiga Kuroi, Kazuki Tanimoto, Kosei Matsue, Masahiro Abe, Tadao Ishida, Shigeki Ito, Hiromi Iwasaki, Junya Kuroda, Hirohiko Shibayama, Kazutaka Sunami, Hiroyuki Takamatsu, Hideto Tamura, Toshiaki Hayashi, Kiwamu Akagi, Takahiro Maeda, Takahiro Yoshida, Ikuo Mori, Tomohiro Shinozaki, Shinsuke Iida
Real-world studies permit inclusion of a more diverse patient population and provide more information on the effectiveness of treatments used in routine clinical practice. This prospective, multicenter, observational study investigated the effectiveness and safety of ixazomib plus lenalidomide and dexamethasone (IRd) in 295 patients with relapsed/refractory multiple myeloma (RRMM) in routine clinical practice in Japan. Patients had a median age of 74 years, 80.0% were aged ≥ 65 years, 42...
September 11, 2023: Annals of Hematology
https://read.qxmd.com/read/37684379/ccdc50-an-essential-driver-involved-in-tumorigenesis-is-a-potential-severity-marker-of-diffuse-large-b-cell-lymphoma
#20
JOURNAL ARTICLE
Yuqi Gong, Hongyan Tong, Fang Yu, Qi Liu, Xianbo Huang, Guoping Ren, Zhongqin Fan, Zhe Wang, Jing Zhao, Zhengrong Mao, Jing Zhang, Ren Zhou
Diffuse Large B Cell Lymphoma (DLBCL) is the most common form of blood cancer. Among the subtypes, the activated B-cell (ABC) subtype is typically more aggressive and associated with worse outcomes. However, the underlying mechanisms are not fully understood. In this study, we performed microarray analysis to identify potential ABC-DLBCL-associated genes. We employed Kaplan-Meier methods and cox univariate analysis to explore the prognostic value of the identified candidate gene Coiled-coil domain containing 50 (CCDC50)...
September 9, 2023: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.